News for BioCryst Pharmaceuticals, Inc. (BCRX.MX)

BioCryst Pharmaceuticals (BCRX) is undergoing a leadership transition following the resignation of its Chief Financial Officer, Anthony Doyle. Doyle had previou

BioCryst (BCRX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

On April 4, 2025, BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company, announced the grant of restricted stock units (RSUs) to 10 newly-hired em

RESEARCH TRIANGLE PARK, N.C., April 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( BCRX) today announced that the compensation committee of Bio

**media[585924]**

BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company specializing in treatments for rare diseases, announced on April 2, 2025, that it will prese

RESEARCH TRIANGLE PARK, N.C., April 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. ( BCRX) today announced that the company plans to present at t

We recently published a list of the 10 Best Small-Cap Stocks to Buy Now. In this article, we are going to take a look at where BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals Inc (BCRX) announced its financial results for the fourth quarter and full year ending December 31, 2024, on February 24, 2025. The com

ORLADEYO Revenue Growth: 34% year-over-year increase for 2024.Total Revenue for Q4 2024: $131.5 million.ORLADEYO Revenue for Q4 2024: $124.2 million.Total Reve

Feb 24, 2025 / 01:30PM GMTOperator Good day and welcome to the BioCryst fourth Quarter 2024 Earnings Call. All participants will be in listen-only mode. (Operat

The following slide deck was published by BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2024 Earnings Conference Call February 24, 2025 8:30 AM ETCompany ParticipantsJohn Bluth - Chief...

BioCryst Pharmaceuticals, Inc. (BCRX) posted a net loss for the fourth quarter of $26.8 million, or $0.13 per share, compared to a net loss of $61.7 million, or $0.

””ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)”” ””FY 2025 ORLADEYO net rev

Revenue: $131.5 million for Q4 2024, surpassing the estimated $130.15 million, marking a 40.8% increase year-over-year.ORLADEYO Net Revenue: $124.2 million for

On February 12, 2025, BioCryst Pharmaceuticals Inc (BCRX) announced that Infarmed, the Portuguese National Authority of Medicines and Health Products, has recom

**media[538607]**

Summary BioCryst Pharmaceuticals Inc (BCRX), a global biotechnology company specializing in treatments for rare diseases, announced that it will release its fou